Search clinical trials for: 177 Lu-PSMA-I&T

Total 251 results

Curium US LLC

Recruiting

Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer (Solar-Recur)

Prostate Cancer | Prostate Adenocarcinoma | Biochemical Recurrence of Malignant Neoplasm of Prostate

United States
Curium US LLC

Recruiting

Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer (Solar-Stage)

Prostate Cancer | Prostate Adenocarcinoma

United States
Radboud University Medical Center

Completed

Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer

Metastatic Clear Cell Renal Cell Carcinoma

Netherlands
Shenzhen Geno-Immune Medical Institute

Recruiting

PSMA/CD70 Bi-specific CAR-T Cell Therapy

Cancer Disease

China
National Cancer Institute (NCI)

Recruiting

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus Everolimus in Patients With Metastatic Unresectable Midgut Neuroendocrine Tumors, NET RETREAT Trial

Metastatic Midgut Neuroendocrine Tumor | Unresectable Midgut Neuroendocrine Tumor | Metastatic Midgut Neuroendocrine Tumor G1 | Metastatic Midgut Neuroendocrine Tumor G2

United States, Canada
Poseida Therapeutics, Inc.

Active, not recruiting

P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)

Neoplasms | Neoplasms by Histologic Type | Urogenital Neoplasms | Neoplasms by Site | Genital Neoplasms, Male | Prostatic Neoplasms | Adenoid Cystic Carcinoma | Mucoepidermoid Carcinoma | Prostate Cancer | Prostatic Neoplasms, Castration-Resistant | Metastatic Castration-resistant Prostate Cancer | Neoplasms... and other conditions

United States
Novartis Pharmaceuticals

Completed

Retrospective Analysis of Patients Re-treated With Lutetium-177 DOTATATE (Lutathera®)

Neuroendocrine Tumor

United States
Shenzhen Geno-Immune Medical Institute
Shenzhen Children's Hospital

Recruiting

4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma

Neuroblastoma

China
Second Affiliated Hospital of Guangzhou Medical...
Guangdong Zhaotai InVivo Biomedicine Co. Ltd.; Hunan Zhaotai Yongren Medical...

Recruiting

GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers

Cancer | Lung Cancer | Immunotherapy | CAR-T Cell

China
National Cancer Institute (NCI)

Recruiting

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

Stage IV Prostate Cancer AJCC v8 | Metastatic Prostate Small Cell Neuroendocrine Carcinoma | Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation | Metastatic Prostate Neuroendocrine Carcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors

Metastatic Digestive System Neuroendocrine Neoplasm | Metastatic Neuroendocrine Tumor

United States
National Cancer Institute (NCI)

Recruiting

Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors

Metastatic Neuroendocrine Tumor

United States
Jonsson Comprehensive Cancer Center

Not yet recruiting

Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)

Prostate Carcinoma | Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) v8

United States
Imperial College London
Advanced Accelerator Applications International SA

Recruiting

Lutathera and ASTX727 in Neuroendocrine Tumours (LANTana)

Neuroendocrine Tumors

United Kingdom
Novartis Pharmaceuticals

Active, not recruiting

A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

China
Novartis Pharmaceuticals

Active, not recruiting

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

China
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors

Neuroendocrine Neoplasm

United States
Stanford University
Novartis Pharmaceuticals

Recruiting

Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery

Gastroenteropancreatic Neuroendocrine Tumor

United States
Novartis Pharmaceuticals

Recruiting

Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

Prostate Cancer

United States
IRCCS San Raffaele

Recruiting

Imaging Guided Surgery to Improve the Detection of Lymph Node Metastases in Prostate Cancer Patients

Prostate Cancer

Italy
Mayo Clinic

Recruiting

Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8

United States
Yale University
Robinhood Foundation; Adelphi University; Docs for Tots

Completed

The Infant- Toddler Climate of Healthy Interactions for Learning and Development (I-T CHILD) (I-T CHILD)

Social Skills | Child Behavior | Child Development | Infant Development

United States
Jonsson Comprehensive Cancer Center
Novartis Pharmaceuticals

Not yet recruiting

Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial

Castration-Resistant Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8

United States
Institut du Cancer de Montpellier - Val d'Aurelle

Recruiting

Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated NET (ReLUTH)

Progressive Disease | Neuroendocrine Tumors | Intestinal Well Differentiated Endocrine Tumor

France
British Columbia Cancer Agency

Withdrawn

177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs

Neuroendocrine Tumors | Carcinoid Tumor | Gastrinoma | Insulinoma | Vipoma | Gastroenteropancreatic Neuroendocrine Tumor | Pulmonary Carcinoid Tumor

Canada
University of California, San Francisco
Merck Sharp & Dohme LLC; Prostate Cancer Foundation

Recruiting

Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer

Prostate Cancer | Prostate Carcinoma | Metastatic Castration-resistant Prostate Cancer | Castrate Resistant Prostate Cancer

United States
Herlev Hospital

Recruiting

A Prospective Comparison of Cardiac Troponin T and Troponin I in the Diagnosis of Myocardial Infarction

Myocardial Infarction

Denmark
University of Miami
United States Department of Defense

Completed

Mindfulness Training for Small Teams

Cognitive Change

United States
Novartis Pharmaceuticals

Active, not recruiting

A Post Marketing Surveillance on Lutathera® in Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumor in Korea

Somatostatin Receptor-positive GEP-NET

Korea, Republic of
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors

Metastatic Pancreatic Neuroendocrine Tumor | Unresectable Pancreatic Neuroendocrine Carcinoma

United States
Imperial College London

Not yet recruiting

Comparing Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases (NELMAS)

Neuroendocrine Tumors
King's College Hospital NHS Trust
Advanced Accelerator Applications

Not yet recruiting

Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy (CHARRT)

Carcinoid Tumor | Carcinoid Syndrome | Carcinoid Heart Disease
IRCCS San Raffaele

Completed

Neoadjuvant PRRT With 177Lu-DOTATATE Followed by Surgery for Resectable PanNET (NeoLuPaNET)

Neuroendocrine Tumors

Italy
National Cancer Institute (NCI)

Recruiting

Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors

Metastatic Pancreatic Neuroendocrine Tumor | Pancreatic Neoplasm | Stage III Pancreatic Neuroendocrine Tumor AJCC v8 | Stage IV Pancreatic Neuroendocrine Tumor AJCC v8 | Unresectable Pancreatic Neuroendocrine Tumor

United States, Canada
Glenn Bauman
London Health Sciences Foundation

Active, not recruiting

Radioligand fOr locAl raDiorecurrent proStaTe cancER (ROADSTER)

Prostate Cancer

Canada
Vanderbilt-Ingram Cancer Center

Recruiting

Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors

Metastatic Digestive System Neuroendocrine Neoplasm | Metastatic Malignant Neoplasm in the Liver | Pancreatic Neuroendocrine Tumor G1 | Pancreatic Neuroendocrine Tumor G2 | Digestive System Neuroendocrine Tumor G1 | Digestive System Neuroendocrine Tumor G2

United States
Inonu University

Completed

Comparison of Size 1 I-gel and ProSeal Laryngeal Mask

Laryngeal Masks

Turkey
Jakob Stenman
Novartis; Advanced Accelerator Applications

Recruiting

177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma (LuDO-N)

Neuroblastoma | Neuroblastoma Recurrent

Sweden, Denmark, Lithuania, Norway, Netherlands
Dana-Farber Cancer Institute
Novartis

Recruiting

LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer

Prostate Cancer | Metastatic Prostate Cancer | Metastatic Castration-resistant Prostate Cancer

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Merck Sharp & Dohme LLC; Lantheus Medical Imaging

Not yet recruiting

PSMA Therapy and Immunotherapy in Kidney Cancer

Metastatic Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma
Advanced Accelerator Applications

Active, not recruiting

Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETs (REAL-LU)

Gastroenteropancreatic Neuroendocrine Tumor

Italy
Erasmus Medical Center

Recruiting

Biomarker Identification of Radionuclide Therapy-induced Radiation Responses (Radio-Marker)

Neuroendocrine Tumors

Netherlands
Ebrahim S Delpassand
Excel Diagnostics and Nuclear Oncology Center

Completed

177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms

Neuroendocrine Tumors

United States
Zhejiang University
Bioray Laboratories

Completed

PD1 Integrated Anti-PSMA CART in Treating Patients With Castrate-Resistant Prostate Cancer

Castrate-Resistant Prostate Cancer

China
ITM Solucin GmbH

Not yet recruiting

Phase I Trial to Determine the Dose and Evaluate the PK of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors (KinLET)

Lymphoma | CNS Tumor | Solid Tumor, Childhood | Somatostatin Receptor Positive | NET
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver

Neuroendocrine Tumors | Liver-Dominant Metastatic Pancreatic Neuroendocrine Tumors

United States
Excel Diagnostics and Nuclear Oncology Center

Withdrawn

Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET. (PUTNET)

Neuroendocrine Tumors | Pheochromocytoma | Paraganglioma | Unknown Primary Tumors | Pulmonary Neuroendocrine Neoplasm | Thymus Carcinoid | Neuroendocrine Skin Carcinoma | Neuroendocrine Breast Tumor | Neuroendocrine Carcinoma Metastatic | Neuroendocrine Neoplasm of Ovary

United States
Shanghai Changzheng Hospital
Bioray Laboratories

Recruiting

Clinical Study of Safety and Efficacy of Enhanced PSMA CAR- T in Refractory CRPC

Castration-resistant Prostate Cancer | Metastatic Castration-resistant Prostate Cancer

China
Zonguldak Bulent Ecevit University

Completed

Effect of Different Supralottic Airway Devicess on Optic Nerve Sheath Diameter

Intracranial Pressure Increase | Supraglottic Airway Device | Optic Nerve Sheath Diameter

Turkey
University of Warmia and Mazury
National Center for Research and Development, Poland; Medical University of... and other collaborators

Unknown

Personalized CAPTEM Radiopeptide Therapy of Advanced, Non-resectable Neuroendocrine Cancer

Neuroendocrine Tumors

Poland

Search clinical trials for: 177 Lu-PSMA-I&T

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tanzania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations